1053631-76-7

Upstream product

• 1054639-43-8 (3aS,4R,8R,8aS)-5-(3-Acetyl-4-fluoro-benzyl)-4,8-dibenzyl-2,2-dimethyl-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-6-one 
• 709-45-5 2-fluoro-5-bromomethyl benzoic acid methyl ester 
• 1053270-08-8 5-{(3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-6-oxo-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl}-2-fluoro-benzoic acid 
• 1053721-45-1 5-{(3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-6-oxo-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl}-2-fluoro-benzoic acid methyl ester 
• 1053635-97-4 5-{(3aS,4R,8R,8aS)-4,8-Dibenzyl-2,2-dimethyl-6-oxo-7-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazol-5-ylmethyl]-hexahydro-1,3-dioxa-5,7-diaza-azulen-5-ylmethyl}-2-fluoro-N-methoxy-N-methyl-benzamide 

Relevant academic research and scientific papers

Nonsymmetric P2/P2' cyclic urea HIV protease inhibitors. Structure- activity relationship, bioavailability, and resistance profile of monoindazole-substituted P2 analogues

Using the structural information gathered from the X-ray structures of various cyclic urea/HIVPR complexes, we designed and synthesized many nonsymmetrical P2/P2'-substituted cyclic urea analogues. Our efforts concentrated on using an indazole as one of t